Novo Holdings REPAIR invest in Mutabilis
January 6th 2020: Novo Holdings REPAIR Impact fund announced a EUR 7 (USD 8) million investment in Mutabilis to accelerate its 2G Dabocins program
READ MOREJanuary 6th 2020: Novo Holdings REPAIR Impact fund announced a EUR 7 (USD 8) million investment in Mutabilis to accelerate its 2G Dabocins program
READ MORETitle of the talk : DISCOVERY OF DABOCINS, A NOVEL CLASS OF NON-BETA-LACTAM PBP INHIBITORS
READ MOREFollowing the integration of Mutabilis’ second programme in ENABLE in April 2018, the ENABLE Portfolio Management Committee has selected a candidate from this programme.
READ MOREMutabilis will be represented at the ASM MICROBE 2019 conference in San-Francisco from June 20th to 24th 2019.
READ MORELike last year, Mutabilis delegates will participate to the Berlin Conference on Novel Antimicrobials and Diagnosstics 2019 on March 14th – 15th 2019.
READ MOREThe World Health Organization had published earlier this year a list of the most concerning pathogens. The WHO continues with a report on the pipeline of antibiotics currently in clinical development to assess how we are going to manage the pathogens of the list.
READ MOREMutabilis has been selected by the European ENABLE project (European Gram-negative Antibacterial Engine), which aims to improve the development of antibiotics against infections caused by multiresistant Gram-negative bacteria.
READ MOREThe DRIVE-AB project is part of the IMI’s New Drug For Bad Bugs (ND4BB) initiative
READ MOREThe new European AMR plan relies on the “One Health” approach
READ MOREThe Office of Health Economic (UK) has released a report that assess the relevance
READ MORE